Tag Archives: Ritu Baral

NGM Biopharmaceuticals (NGM) Gets a Buy Rating from Cowen & Co.

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on NGM Biopharmaceuticals (NGM – Research Report), with a price target of $30.00. The company’s shares closed last Monday at $11.66. According to TipRanks.com, Baral

Cowen & Co. Keeps Their Buy Rating on Avrobio (AVRO)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Avrobio (AVRO – Research Report) yesterday. The company’s shares closed last Monday at $10.08, close to its 52-week low of $9.95. According to TipRanks.com, Baral is a 4-star analyst

Cowen & Co. Keeps a Buy Rating on Albireo Pharma (ALBO)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Albireo Pharma (ALBO – Research Report) yesterday and set a price target of $39.00. The company’s shares closed last Monday at $22.37. According to TipRanks.com, Baral is a 5-star

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Arbutus Biopharma (NASDAQ: ABUS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY – Research Report) and Arbutus Biopharma (ABUS – Research Report) with bullish sentiments. Alnylam Pharma (ALNY) Cowen & Co.

Cowen & Co. Maintains Their Buy Rating on Sangamo Biosciences (SGMO)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today. The company’s shares closed last Monday at $8.32. According to TipRanks.com, Baral is a 5-star analyst with an average return of 17.7%

Morphic Holding (MORF) Receives a Buy from Cowen & Co.

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Morphic Holding (MORF – Research Report) today. The company’s shares closed last Monday at $17.95. According to TipRanks.com, Baral is a 5-star analyst with an average return of 17.7%